SCHEDULE: Goldman Sachs Reports Stake in Amicus Therapeutics

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 5.3% of Amicus Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• This filing is a Schedule 13G, indicating a passive investment by The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC in Amicus Therapeutics, Inc.
• As of March 31, 2026, the reporting entities collectively beneficially owned 16,782,162.81 shares of Amicus Therapeutics, Inc. common stock.
• This ownership stake represents 5.3% of the class of securities.
• The filing specifies that Goldman Sachs & Co. LLC is a broker-dealer and investment adviser, and a subsidiary of The Goldman Sachs Group, Inc.
• The reporting entities certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a passive ownership stake without providing new operational or financial information about the company.

Positives

• Goldman Sachs, a major financial institution, holds a significant stake, which could be interpreted as a positive signal of confidence in Amicus Therapeutics.
• The filing indicates a passive investment strategy, suggesting no intent to control or influence the company's operations, which is typical for institutional investors.

Negatives

• The filing does not contain any financial performance data or operational updates for Amicus Therapeutics, only ownership information.
• The nature of the filing (Schedule 13G) implies a passive role, meaning no direct contribution to the company's strategy or growth is disclosed.

Risks

• The primary risk is the potential for market fluctuations affecting the value of the 16,782,162.81 shares held by Goldman Sachs.
• Any change in Goldman Sachs' investment strategy or market conditions could lead to significant selling pressure on Amicus Therapeutics' stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Amicus Therapeutics' future performance. It solely reports current beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings from major financial institutions like Goldman Sachs often signal significant institutional interest in a company's stock, though this filing specifically denotes a passive investment rather than an activist stake.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional holding, which can influence market perception and trading liquidity.
• Management of Amicus Therapeutics: The passive nature of the stake suggests no immediate pressure for strategic changes from Goldman Sachs.

Next Steps

• Amicus Therapeutics may see continued institutional interest, as reflected by this filing.
• Goldman Sachs will continue to monitor its investment in Amicus Therapeutics, with potential for future filings if ownership levels change significantly.

Key Dates

Keywords

Amicus Therapeutics, Schedule 13G, Goldman Sachs, Beneficial Ownership, Common Stock, SEC Filing, Investment, Passive Investment